Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)
ANNOUNCEMENT
UNAUDITED FINANCIAL RESULTS OF CR SANJIU
FOR THE SIX MONTHS ENDED 30 JUNE 2020
On 25 August 2020, CR Sanjiu released its interim report for the six months ended 30 June 2020.
China Resources Sanjiu Medical & Pharmaceutical Company Limited（華潤三九醫藥股 份有限公司）("CR Sanjiu") is a company incorporated in the People's Republic of China (the "PRC"). The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to 63.60% by China Resources Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") and is a subsidiary of the Company.
On 25 August 2020, CR Sanjiu released its interim report for the six months ended 30 June 2020 (the "CR Sanjiu Unaudited Financials"). Set out below is the key financial information of the CR Sanjiu Unaudited Financials:
As of | As of | ||
30 June | 31 December | Increase/ | |
2020 | 2019 | decrease | |
(RMB) | (RMB) | (%) | |
(unaudited) | (audited) | ||
Total assets | 20,112,442,057.74 | 20,103,525,732.24 | 0.04% |
Net assets attributable to shareholders of | |||
the listed company | 13,203,021,120.84 | 12,563,844,411.13 | 5.09% |
1
For the six months ended 30 June | Increase/ | ||
2020 | 2019 | decrease | |
(RMB) | (RMB) | (%) | |
(unaudited) | (unaudited) | ||
Revenue | 5,832,422,066.78 | 7,166,809,328.65 | -18.62% |
Net profit attributable to the shareholders of | |||
the listed company | 1,060,824,999.43 | 1,722,327,728.56 | -38.41% |
Net profit attributable to the shareholders of | |||
the listed company (after extraordinary | |||
gains or losses) | 922,607,536.51 | 976,520,967.14 | -5.52% |
Net cash flow from operating activities | 1,067,408,397.90 | 1,185,931,159.16 | -9.99% |
Basic earnings per share (RMB/share) | 1.08 | 1.76 | -38.64% |
Diluted earnings per share (RMB/share) | 1.08 | 1.76 | -38.64% |
Weighted average return on net asset (%) | 8.23% | 15.23% | -7 |
percentage points |
Note: For the six months ended 30 June 2020, CR Sanjiu realised net profit attributable to the shareholders of listed company of RMB1,060,824,999.43, a year-on-year decrease of 38.41% is primarily attributable
to the completion of disposal of its equity interest in Shenzhen Sanjiu Hospital Co., Ltd（深圳市三九 醫院有限公司）, resulting in a net gain (after tax) of approximately RMB680 million to CR Sanjiu.
Excluding the above impact, CR Sanjiu achieved a year-on-year increase of approximately 2% in net profit attributable to the shareholders of listed company.
The CR Sanjiu Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to CR Sanjiu only and does not represent or provide a complete view of the operational or financial status of the Group. Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.
For further details of the CR Sanjiu Unaudited Financials, please refer to the interim report for the six months ended 30 June 2020 published by CR Sanjiu on the website of the Shenzhen Stock Exchange (www.szse.cn).
By order of the Board of Directors
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Chairman
Shenzhen, 26 August 2020
As of the date of this announcement, the Board comprises Mr. WANG Chuncheng as chairman and non-executive Director, Mr. HAN Yuewei, Mr. LI Xiangming and Mdm. WENG Jingwen as executive Directors, Mr. YU Zhongliang, Mdm. GUO Wei, Mr. WANG Shouye and Mr. LYU Ruizhi as non-executive Directors and Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.
2